Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis treated in daily practice. In a sub-group, the effectiveness of abrocitinib on hand eczema was evaluated. A total of 103 patients from the BioDay registry were included in the study: week 4 (n = 95), week 16 (n= 61) and week 28 (n= 39). At week 28, the Eczema Area and Severity Index (EASI)-50/75/90 was achieved by 81.8%, 57.6%, and 18.2%, respectively, and the weekly average pruritus numerical rating sca-le <= 4 by 62.9%. The effectiveness of abrocitinib was not significantly different between dupilumab non-re-sponders and dupilumab-naive patients/responders, and between upadacitinib non-responders and upada-citinib-naive patients/responders. Mean +/- standard de-viation Hand Eczema Severity Index decreased from 27.4 +/- 27.7 at baseline to 7.7 +/- 12.1 at week 28 (n = 31). Thirty-two patients (31.1%) discontinued treatment due to ineffectiveness (n= 17), adverse events (n = 9) or both (n= 3). The most frequently reported adverse event was nausea (n= 28). In conclusion, abrocitinib is an effective treatment for atopic dermatitis and can be effective for patients with previous inadequate re-sponse to dupilumab or upadacitinib. Furthermore, hand eczema can improve in patients treated with ab-rocitinib for atopic dermatitis.